Clinical Trials · NCT04050553
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 42
- Start date
- Feb 2020
- Locations
- 1 site, Austria
- Primary endpoint
- Change in Mean Glucagon Concentration During Induced Hypoglycemia From Target Plasma Glucose (PG) Concentration of 100 Milligrams Per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL